Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Understanding and circumventing resistance to anticancer monoclonal antibodies Reslan L; Dalle S; Dumontet CMAbs 2009[May]; 1 (3): 222-9With the widespread use of therapeutic monoclonal antibodies in the treatment of patients with cancer, resistance to these agents has become a major issue. Preclinical models of drug action or resistance have contributed to unravel the main mechanisms of resistance, involving both tumor-associated and host related factors. However our understanding of how a monoclonal antibody destroys cancer cells in a patient and why it one day stops being effective are still far from being complete. This review focuses on the available data on mechanisms of action and resistance to rituximab and includes some additional information for other monoclonal antibodies. Innovative approaches designed to overcome resistance, such as combination immunotherapy, costimulation with cytokines or growth factors are presented.|*Immunization, Passive[MESH]|Animals[MESH]|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Antibody-Dependent Cell Cytotoxicity/*drug effects/immunology[MESH]|Cytokines/therapeutic use[MESH]|Drug Resistance, Neoplasm/drug effects/*immunology[MESH]|Drug Therapy, Combination[MESH]|Humans[MESH]|Intercellular Signaling Peptides and Proteins/therapeutic use[MESH]|Neoplasms/*drug therapy/immunology[MESH]|Rituximab[MESH] |
